Novel BTK Inhibitor Succeeds in Heavily Pretreated Immune Thrombocytopenia

(MedPage Today) -- SAN DIEGO -- Treatment with an investigational oral inhibitor of Bruton's tyrosine kinase (BTK) was safe and boosted platelet counts in heavily pretreated patients with immune thrombocytopenia (ITP), a phase III trial showed...